(ARCMED_2020_1173)

To editor,

The author shares some ideas about the use of amantadine for the treatment of people with COVID-19, the author mentions an interesting article by Dr. Kobylecki where he mentions a mortality rate of 22.4% for Parkinson\'s patients studied between January 1, 2020 and May 31, 2020, where 3 cases were confirmed positive for COVID-19 ([@bib1]).

It is important to note the following:a) In Dr. Kobylecki\'s study, they do not mention whether the Parkinson\'s patients were medicated with Amantadine.b) I reviewed an article cited by Dr. Kobylecki, entitled "Effects of COVID-19 on Parkinson\'s Disease Clinical Features: A Community-Based Case-Control Study DOI: 10,1002/mds.28170. In that observational study of people with Parkinson\'s, 8.5% were positive for COVID-19. Within the characteristics of the population, none were medicated with amantadine (Table 1. Characteristics of the study population) ([@bib2]).

The fact that Parkinson\'s patients get COVID-19 is probably because their main medication was Levodopa and not amantadine.

I would like to point out that amantadine is an antiviral that is able to mitigate the effects of COVID-19 and works excellently ([@bib3], [@bib4], [@bib5]).
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